Login to Your Account

Clinic Roundup

Monday, May 20, 2013
• Insero Health Inc., of Miami, reported top-line results from a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription